ClinicalTrials.gg

Program

XKH001

A development code. Also written as “XKH001 Injection” and “XKH001Injection”.

Its studies are mostly in Asthma · Pulmonary Disease, Chronic Obstructive · Dermatitis, Atopic, led by 2 companies.

Furthest: phase 2, since Dec 23, 20246 company-led studies, 3 open or runningNext primary completion: Apr 1, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Zhejiang Kanova Biopharmaceutical43 open or runningphase 2since Dec 23, 2024Dec 23, 2024Apr 1, 2027phase 1 · NCT07757659
Beijing Kanova Biopharmaceutical20 open or runningphase 2since Jul 24, 2023Oct 13, 2021none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 13, 2021First study: phase 1 study in Healthy AdultsNew to Beijing Kanova BiopharmaceuticalBeijing Kanova Biopharmaceutical · NCT05128409 · 35 enrolled · China
  2. Jul 24, 2023Phase 2 study in AsthmaBeijing Kanova Biopharmaceutical · NCT05991661 · 24 enrolled · China
  3. Dec 23, 2024Zhejiang Kanova Biopharmaceutical's first study: phase 1 study in AsthmaNew to Zhejiang Kanova BiopharmaceuticalZhejiang Kanova Biopharmaceutical · NCT07070297 · 12 enrolled · China
  4. Dec 23, 2024Phase 2 study in Dermatitis, AtopicZhejiang Kanova Biopharmaceutical · NCT07054736 · 120 planned · China
  5. Mar 31, 2026Phase 2 study in Pulmonary Disease, Chronic ObstructiveZhejiang Kanova Biopharmaceutical · NCT07519499 · 75 planned
  6. Jul 28, 2026Phase 1 study in Healthy AdultZhejiang Kanova Biopharmaceutical · NCT07757659 · 2 planned · Australia

Ahead

  1. Apr 1, 2027Primary completion: phase 1 study in Healthy AdultZhejiang Kanova Biopharmaceutical · NCT07757659
  2. Dec 1, 2027Primary completion: phase 2 study in Pulmonary Disease, Chronic ObstructiveZhejiang Kanova Biopharmaceutical · NCT07519499

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07757659Healthy Adult · Australia1Not yet recruitingZhejiang Kanova BiopharmaceuticalApr 1, 20272
NCT07519499Pulmonary Disease, Chronic Obstructive2Not yet recruitingZhejiang Kanova BiopharmaceuticalDec 1, 202775
NCT07070297Asthma · China1CompletedZhejiang Kanova BiopharmaceuticalOct 10, 202412
NCT07054736Dermatitis, Atopic · China2Not yet recruitingZhejiang Kanova BiopharmaceuticalOct 1, 2025120
NCT05991661Asthma · China2CompletedBeijing Kanova BiopharmaceuticalFeb 20, 202424
NCT05128409Healthy Adults · China1UNKNOWNBeijing Kanova BiopharmaceuticalOct 1, 202435

How it is read

Names in the registry

  • “XKH001 Injection”, 5 entries
  • “XKH001Injection”, 1 entry

Codes read as this program: XKH001.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.